HGP – MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies
– Preclinical research to focus on developing therapies based on MaxCyte’s proprietary CARMA platform
– CARMA has potential for broad applicability against solid or liquid tumor indications
Gaithersburg, MD, December 21, 2016 – MaxCyte®, Inc. today announces a strategic collaboration with Washington University in St. Louis, a leading institution in acute myeloid leukemia (AML) research. MaxCyte and the university will develop unique immunotherapy drug candidates, based on MaxCyte’s proprietary cell engineering platform technology, CARMA.
CARMA allows simple and rapid manufacture of advanced cancer treatments that utilize a patient’s own immune system and is differentiated from traditional CAR therapy due to its use of mRNA to
engineer immune cells delivered back into a patient. By utilizing transient expression via mRNA delivery, CARMA allows control over severe adverse effects, opening the high potency of CAR immunotherapies to a broader range of cancers than traditional CAR approaches.
“We’re excited to initiate this collaboration with Washington University in St. Louis, one of the leading medical research centers worldwide, to develop a new generation of CAR therapy for blood
cancers using MaxCyte’s CARMA therapeutic platform,” said Doug Doerfler, President & CEO of MaxCyte, Inc. “This collaboration is a natural extension of our efforts in this new class of therapies, given our previously announced collaboration with the Johns Hopkins Kimmel Cancer Center for pre-clinical development of CAR therapy for solid cancers. Our CARMA platform shows great promise for developing therapies for patients with both solid and liquid tumor types. It provides rapid, cost-effective manufacturing and delivery of cellular therapies to patients without many of the toxicities associated with other CAR-based approaches.”
John DiPersio, M.D., Ph.D., Chief of the Division of Oncology at Washington University School of Medicine and Deputy Director of the Siteman Cancer Center, and members of his team will collaborate with MaxCyte to conduct preclinical research with a focus on developing a potential investigational CAR therapy targeting acute myeloid leukemia and other related blood cancers.
Financial terms were not disclosed.
To view the full article, please click here.